Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 9.52% |
| 10 | Vivos Therapeutics | 5.18 Mn | 3.38 Mn | 2.95 Mn | 19.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.86% |
| Dec 31, 2025 | 179.67% |
| Sep 30, 2025 | -41.45% |
| Jun 30, 2025 | 15.22% |
| Mar 31, 2025 | 0.55% |
| Dec 31, 2024 | -24.41% |
| Sep 30, 2024 | -24.21% |
| Jun 30, 2024 | -64.23% |
| Mar 31, 2024 | -16.78% |
| Dec 31, 2023 | 99.39% |
| Sep 30, 2023 | -236.65% |
| Jun 30, 2023 | 281.72% |
| Mar 31, 2023 | 112.59% |